title: Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.
authors.affiliation: Department of Dermatology, University of Heidelberg, Voßstreet 2, DE-69115 Heidelberg, Germany.
authors.forename: Mona
authors.initials: M
authors.lastname: Bidier
authors.forename: Carolin
authors.initials: C
authors.lastname: Zschoche
authors.forename: Patrick
authors.initials: P
authors.lastname: Gholam
authors.forename: Alexander H
authors.initials: AH
authors.lastname: Enk
authors.forename: Eva N
authors.initials: EN
authors.lastname: Hadaschik
mesh_terms: D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D053718:Scleromyxedema / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors